Mortality and Causes of Death in Patients with Sporadic Inclusion Body Myositis: Survey Study Based on the Clinical Experience of Specialists in Australia, Europe and the USA
暂无分享,去创建一个
B. Tseng | F. Mastaglia | T. Lloyd | J. Kissel | I. Lundberg | O. Benveniste | M. Needham | K. Sivakumar | M. de Visser | D. Hilton‐Jones | T. Mozaffar | L. Christopher‐Stine | A. Corbett | C. Demuro | Jens Schmidt | M. Price | V. Barghout
[1] J. Gran,et al. High prevalence of inclusion body myositis in Norway; a population‐based clinical epidemiology study , 2015, European journal of neurology.
[2] F. Mastaglia,et al. Sleep disordered breathing and subclinical impairment of respiratory function are common in sporadic inclusion body myositis , 2014, Neuromuscular Disorders.
[3] L. Servais,et al. Four-year longitudinal study of clinical and functional endpoints in sporadic inclusion body myositis: Implications for therapeutic trials , 2014, Neuromuscular Disorders.
[4] L. Crofford,et al. New Insights into the Benefits of Exercise for Muscle Health in Patients with Idiopathic Inflammatory Myositis , 2014, Current Rheumatology Reports.
[5] P. Carstens,et al. Diagnosis, pathogenesis and treatment of myositis: recent advances , 2014 .
[6] E. Scarano,et al. Sleep disordered breathing in a cohort of patients with sporadic inclusion body myositis , 2013, Clinical Neurophysiology.
[7] B. Weinshenker,et al. Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis , 2013, Multiple sclerosis.
[8] I. Nonaka,et al. Increase in number of sporadic inclusion body myositis (sIBM) in Japan , 2012, Journal of Neurology.
[9] David Hilton-Jones,et al. Long-term observational study of sporadic inclusion body myositis. , 2011, Brain : a journal of neurology.
[10] J. Verschuuren,et al. A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities. , 2011, Brain : a journal of neurology.
[11] Y. Parman,et al. Sporadic-inclusion body myositis (s-IBM) is not so prevalent in Istanbul/Turkey: a muscle biopsy based survey , 2011, Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology.
[12] R. Barohn,et al. Inclusion body myositis: old and new concepts , 2009, Journal of Neurology, Neurosurgery & Psychiatry.
[13] F L Mastaglia,et al. Sporadic inclusion body myositis: variability in prevalence and phenotype and influence of the MHC. , 2009, Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology.
[14] J. Holton,et al. Sporadic inclusion body myositis: an unsolved mystery. , 2009, Acta reumatologica portuguesa.
[15] Allan D. Kirk,et al. Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis , 2009, Brain : a journal of neurology.
[16] Timothy Day,et al. Prevalence of sporadic inclusion body myositis and factors contributing to delayed diagnosis , 2008, Journal of Clinical Neuroscience.
[17] J. Kasperbauer,et al. Dysphagia in Inclusion Body Myositis: Clinical Features, Management, and Clinical Outcome , 2008, American journal of physical medicine & rehabilitation.
[18] I. Lundberg,et al. Mortality in idiopathic inflammatory myopathies. , 2008, Clinical and experimental rheumatology.
[19] F L Mastaglia,et al. Inflammatory muscle diseases. , 2008, Neurology India.
[20] F L Mastaglia,et al. Sporadic inclusion body myositis: Phenotypic variability and influence of HLA-DR3 in a cohort of 57 Australian cases , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.
[21] A. Shatunov,et al. T cell receptor profiling in muscle and blood lymphocytes in sporadic inclusion body myositis , 2007, Neurology.
[22] Marinos C. Dalakas,et al. Upregulation of thrombospondin-1(TSP-1) and its binding partners, CD36 and CD47, in sporadic inclusion body myositis , 2007, Journal of Neuroimmunology.
[23] Marinos C. Dalakas,et al. β‐Amyloid is a substrate of autophagy in sporadic inclusion body myositis , 2007 .
[24] K J Felice,et al. Inclusion Body Myositis in Connecticut: Observations in 35 Patients During an 8-Year Period , 2001, Medicine.
[25] R. Griggs,et al. A prospective natural history study of inclusion body myositis , 2001, Neurology.
[26] F. Breedveld,et al. Epidemiology of inclusion body myositis in the Netherlands: A nationwide study , 2000, Neurology.
[27] F L Mastaglia,et al. Prevalence of sporadic inclusion body myositis in Western Australia , 2000, Muscle & nerve.
[28] A. Oldfors,et al. Inclusion body myositis: clinical, morphological, physiological and laboratory findings in 18 cases , 1994, Acta Neurologica Scandinavica.
[29] W J Litchy,et al. Inclusion body myositis. Observations in 40 patients. , 1989, Brain : a journal of neurology.
[30] N. Dalkey,et al. An Experimental Application of the Delphi Method to the Use of Experts , 1963 .
[31] C. Mazia. A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities , 2012 .
[32] J. Lünemann,et al. Beta-amyloid is a substrate of autophagy in sporadic inclusion body myositis. , 2007, Annals of neurology.
[33] S. Munshi,et al. Inclusion body myositis: an underdiagnosed myopathy of older people. , 2006, Age and ageing.
[34] Baziel G M van Engelen,et al. Inclusion body myositis. Clinical features and clinical course of the disease in 64 patients. , 2005, Journal of neurology.
[35] Richard J. Barohn,et al. Inclusion body myositis , 2000, Current treatment options in neurology.
[36] D. Buchholz,et al. Dysphagia in patients with inclusion body myositis. , 1999, Dysphagia.